Aldosterone-induced osteopontin gene transcription in vascular smooth muscle cells involves glucocorticoid response element

Hypertension Research

Volumn 34, Issue 12, 2011, Pages 1283-1287

  Kiyosue, Arihiro ^a   Nagata, Daisuke ^a   Myojo, Masahiro ^a   Sato, Tomohiko ^a   Takahashi, Masao ^a   Satonaka, Hiroshi ^a   Nagai, Ryozo ^a   Hirata, Yasunobu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

aldosterone; glucocorticoid response element; mineralocorticoid receptor; osteopontin

Indexed keywords

EPLERENONE; GLUCOCORTICOID; LUCIFERASE; OSTEOPONTIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ASSAY; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSCRIPTION; MALE; NONHUMAN; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ALDOSTERONE; ANIMALS; CELLS, CULTURED; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GLUCOCORTICOIDS; MALE; MYOCYTES, SMOOTH MUSCLE; OSTEOPONTIN; PLASMIDS; PROMOTER REGIONS, GENETIC; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RESPONSE ELEMENTS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 82955201853     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.119     Document Type: Article

References (36)

1. Mick VE, Itani OA, Loftus RW, Husted RF, Schmidt TJ, Thomas CP. The alpha-subunit of the epithelial sodium channel is an aldosterone-induced transcript in mammalian collecting ducts, and this transcriptional response is mediated via distinct cis-elements in the 5¢-flanking region of the gene. Mol Endocrinol 2001; 15: 575-588. (Pubitemid 32324439)
2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717. (Pubitemid 29407370)
3. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118: 1643-1650.
4. Pascual-Le Tallec L, Lombes M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol 2005; 19: 2211-2221. (Pubitemid 41252817)
5. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005; 46: 1227-1235. (Pubitemid 43189712)
6. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810. (Pubitemid 35217013)
7. Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, Hirata Y, Naruse M. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006; 48: 165-171. (Pubitemid 44297539)
8. Rocha R, Stier Jr CT. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001; 12: 308-314. (Pubitemid 33714222)
9. Yoshida M, Ma J, Tomita T, Morikawa N, Tanaka N, Masamura K, Kawai Y, Miyamori I. Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest Heart Fail 2005; 11: 12-16.
10. Cai TQ, Wong B, Mundt SS, Thieringer R, Wright SD, Hermanowski-Vosatka A. Induction of 11beta-hydroxysteroid dehydrogenase type 1 but not-2 in human aortic smooth muscle cells by inflammatory stimuli. J Steroid Biochem Mol Biol 2001; 77: 117-122. (Pubitemid 32476819)
11. Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 1985; 232: 715-724. (Pubitemid 16207308)
12. Butler WT. The nature and significance of osteopontin. Connect Tissue Res 1989; 23: 123-136.
13. Murry CE, Giachelli CM, Schwartz SM, Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol 1994; 145: 1450-1462. (Pubitemid 24378499)
14. Uaesoontrachoon K, Yoo HJ, Tudor EM, Pike RN, Mackie EJ, Pagel CN. Osteopontin and skeletal muscle myoblasts: association with muscle regeneration and regulation of myoblast function in vitro. Int J Biochem Cell Biol 2008; 40: 2303-2314.
15. Yamamoto N, Nakashima T, Torikai M, Naruse T, Morimoto J, Kon S, Sakai F, Uede T. Successful treatment of collagen-induced arthritis in non-human primates by chimeric anti-osteopontin antibody. Int Immunopharmacol 2007; 7: 1460-1470. (Pubitemid 47302883)
16. Seiffge D. Protective effects of monoclonal antibody to VLA-4 on leukocyte adhesion and course of disease in adjuvant arthritis in rats. J Rheumatol 1996; 23: 2086-2091.
17. Hirota S, Imakita M, Kohri K, Ito A, Morii E, Adachi S, Kim HM, Kitamura Y, Yutani C, Nomura S. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol 1993; 143: 1003-1008.
18. Giachelli CM, Liaw L, Murry CE, Schwartz SM, Almeida M. Osteopontin expression in cardiovascular diseases. Ann NY Acad Sci 1995; 760: 109-126.
19. Gauer S, Hauser IA, Obermuller N, Holzmann Y, Geiger H, Goppelt-Struebe M. Synergistic induction of osteopontin by aldosterone and inflammatory cytokines in mesangial cells. J Cell Biochem 2008; 103: 615-623. (Pubitemid 351171932)
20. Irita J, Okura T, Manabe S, Kurata M, Miyoshi K, Watanabe S, Fukuoka T, Higaki J. Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension. Am J Hypertens 2006; 19: 293-297. (Pubitemid 43261511)
21. Irita J, Okura T, Kurata M, Miyoshi K, Fukuoka T, Higaki J. Osteopontin in rat renal fibroblasts: functional properties and transcriptional regulation by aldosterone. Hypertension 2008; 51: 507-513. (Pubitemid 351156440)
22. Nagata D, Hirata Y, Suzuki E, Kakoki M, Hayakawa H, Goto A, Ishimitsu T, Minamino N, Ono Y, Kangawa K, Matsuo H, Omata M. Hypoxia-induced adrenomedullin production in the kidney. Kidney Int 1999; 55: 1259-1267. (Pubitemid 29157123)
23. Nagai Y, Miyata K, Sun GP, Rahman M, Kimura S, Miyatake A, Kiyomoto H, Kohno M, Abe Y, Yoshizumi M, Nishiyama A. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 2005; 46: 1039-1045.
24. Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, Nagai Y, Nakamura E, Yoshizumi M, Shokoji T, Kimura S, Kiyomoto H, Tsujioka K, Kohno M, Tamaki T, Kajiya F, Abe Y. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 2005; 45: 710-716. (Pubitemid 40418370)
25. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800. (Pubitemid 36513325)
26. O'Brien ER, Garvin MR, Stewart DK, Hinohara T, Simpson JB, Schwartz SM, Giachelli CM. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 1994; 14: 1648-1656.
27. Gomez-Ambrosi J, Catalan V, Ramirez B, Rodriguez A, Colina I, Silva C, Rotellar F, Mugueta C, Gil MJ, Cienfuegos JA, Salvador J, Fruhbeck G. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 2007; 92: 3719-3727. (Pubitemid 47435361)
28. Duvall CL, Weiss D, Robinson ST, Alameddine FM, Guldberg RE, Taylor WR. The role of osteopontin in recovery from hind limb ischemia. Arterioscler Thromb Vasc Biol 2008; 28: 290-295. (Pubitemid 351161202)
29. Matsui Y, Rittling SR, Okamoto H, Inobe M, Jia N, Shimizu T, Akino M, Sugawara T, Morimoto J, Kimura C, Kon S, Denhardt D, Kitabatake A, Uede T. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23: 1029-1034. (Pubitemid 36713556)
30. Sugiyama T, Yoshimoto T, Hirono Y, Suzuki N, Sakurada M, Tsuchiya K, Minami I, Iwashima F, Sakai H, Tateno T, Sato R, Hirata Y. Aldosterone increases osteopontin gene expression in rat endothelial cells. Biochem Biophys Res Commun 2005; 336: 163-167. (Pubitemid 41253417)
31. Takemoto M, Yokote K, Yamazaki M, Ridall AL, Butler WT, Matsumoto T, Tamura K, Saito Y, Mori S. Enhanced expression of osteopontin by high glucose. Involvement of osteopontin in diabetic macroangiopathy. Ann NY Acad Sci 2000; 902: 357-363. (Pubitemid 30389148)
32. Li G, Oparil S, Kelpke SS, Chen YF, Thompson JA. Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation 2002; 106: 854-859.
33. Renault MA, Jalvy S, Potier M, Belloc I, Genot E, Dekker LV, Desgranges C, Gadeau AP. UTP induces osteopontin expression through a coordinate action of NFkappaB, activator protein-1, and upstream stimulatory factor in arterial smooth muscle cells. J Biol Chem 2005; 280: 2708-2713. (Pubitemid 40189376)
34. Abe K, Nakashima H, Ishida M, Miho N, Sawano M, Soe NN, Kurabayashi M, Chayama K, Yoshizumi M, Ishida T. Angiotensin II-induced osteopontin expression in vascular smooth muscle cells involves Gq/11, Ras, ERK, Src and Ets-1. Hypertens Res 2008; 31: 987-998. (Pubitemid 351895043)
35. Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol 2001; 280: F181-F192.
36. Kitagawa H, Yanagisawa J, Fuse H, Ogawa S, Yogiashi Y, Okuno A, Nagasawa H, Nakajima T, Matsumoto T, Kato S. Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. Mol Cell Biol 2002; 22: 3698-3706. (Pubitemid 34525213)